Ultimately, the alteration of pluripotent-like gene signatures via blocking G9a activity reduced tumor-initiating activity and restored intestinal differentiation in human colorectal cancer models, supporting the concept of targeting embryonic roots of tumors as a promising therapeutic strategy. This evidence concerns the gene EHMT2 and neoplasm.